光子修復(fù)凝膠一類醫(yī)療器械備案全套資料   [更多]

求DOF期刊2018年10-12期文獻(xiàn)   [更多]

1. Miller J. Ogidigben, Teh-Ching Chu and David E. Potter. Naphazoline-induced neuroendocrine changes Increases in ANP and cGMP levels 2. Robert J. Dockhorn and Thomas G. Duckett. Comparison of Naphcon-A and Its components 3. Mark B, Abelson MD, Salim I, et al. Tolerance and absence of rebound vasodilation following topical ocular decongestant usage 4. Ogidigben MJ, Chu TC, Potter DE. Naphazoline-induced suppression of aqueous humor pressure and flowinvolvement of central and peripheral alpha(2) I(1) receptors 5. The efficacy of long-term treatment with Tolvaptan to prolong the time until dialysis initiation in patients with chronic kidney disease and heart failure 6. Renoprotective effects of tolvaptan in hypertensive heart failure rats depend on renal decongestion 7. Tolvaptan Efficiently Reduces Intracellular Fluid Working Toward a Potential Treatment Option for Cellular Edema 8. Analysis of tolvaptan non-responders and outcomes of tolvaptan treatment of ascites 9. Tolvaptan in Japanese patients with later-stage autosomal dominant polycystic kidney disease 10. Safety and Effectiveness of Tolvaptan Administration after Total Arch Replacement 11. Nephrol Dial Transplant. 2018 Oct 12. doi 10.1093ndtgfy297. [Epub ahead of print] 12. Nephrol Dial Transplant. 2018 Oct 11. doi 10.1093ndtgfy298. [Epub ahead of print] 13. Development and validation of RP-HPLC method for simultaneous estimation of Ofloxacin and Ornidazole inpresence of Ornidazole Impurity in combined pharmaceutical dosage form 14. Stability-indicating methods for the determination of Ornidazole in the presence of its degradate according to ICH guidelines 15. A sensitive HPLC method of determination of 2-methyl 5-nitro imidazole & reaction mass of intermediates of ornidazole in ornidazole bulk manufacturing 16. Development and validation of a reversed-phase HPLC method for the analysis of ornidazole in pharmaceutical dosage forms 17. On the hydrolytic behavior of tinidazole, metronidazole,   [更多]

1.Bulletin of the Chemical Society of Japan, Volume 26, Pages 119-122, Journal, 1953 2.Dalton Transactions 2017,vol. 46, # 5, p. 1510 - 1519 3.Design and evaluation of ophthalmic pharmaceutical products. In Banker GS, Rhodes CT, eds. Modern Pharmaceutics, 4th edn. New York Marcel Dekker, 2002 415-478 4.Ixabepilone plus capecitabine with capecitabine alone for metastatic breast cancer 5.Journal of Photochemistry and Photobiology, B Biology, Volume 97, Issue 1, Pages 18-21, Journal, 2009 6.Journal of Photochemistry and Photobiology, B Biology, Volume 115, Pages 51-57, Journal; Online Computer File, 2012 7.Nair AD, Lach JL. The kinetics of degradation of chlorobutanol. J Am Pharm Assoc (Sci) 1959; 48 390-395. 8.Phase II study of the halichondrin B analog eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline, a taxane, and capecitabine 9.Plasma?renin?activity-guided strategy for the management of hypertension. 10.Stability of chlorobutanol in aqueous solutions Journal of the American Pharmaceutical Association (1961), Volume 6, Issue 7, July 1966, Pages 372-373 11.Talanta, Volume 146, Pages 732-736, Journal; Online Computer File, 2016   [更多]

求購(gòu)磷酸西格列汀片信息   [更多]

高價(jià)求《云南省中藥飲片標(biāo)準(zhǔn)》葛根粉云信息，如果你有標(biāo)準(zhǔn)，請(qǐng)聯(lián)系我，價(jià)格可談   [更多]

求購(gòu)達(dá)托霉素信息   [更多]

RT 尋求一個(gè)標(biāo)準(zhǔn)文件，不是32頁(yè)那個(gè)！ 社會(huì)保險(xiǎn)藥品分類與代碼(LD/T 01-2017)   [更多]

需肌苷注射液、三磷酸腺苷二鈉注射液、注射用輔酶A英文說(shuō)明書(shū)各一份   [更多]

1. 年凈利潤(rùn)2000-3000萬(wàn)。 2. 有核心產(chǎn)品。 3. 有被收購(gòu)意向。 提供信息請(qǐng)包括：企業(yè)名稱、聯(lián)系人、聯(lián)系方式 信息經(jīng)核對(duì)真實(shí)，方可獲得賞金，謝謝藥智的戰(zhàn)友們。   [更多]